• P-ISSN 2277-3525 E-ISSN 2582-7901

Journal of Multidisciplinary
Dental Research


Journal of Multidisciplinary Dental Research

Volume: 7, Issue: 2, Pages: 55-59

Case Report

Comprehensive Management of a Patient with Drug Induced Gingival Overgrowth and Metabolic Syndrome

Received Date:05 June 2021, Accepted Date:06 August 2021, Published Date:20 August 2021


Periodontitis and metabolic syndrome demonstrate a bidirectional relationship complicated by multiple risk factors. Gingival overgrowth (GO) is a manifestation of exaggerated inflammatory response of the gingivae in response to biofilm and varying local and systemic risk factors which include medications such as antihypertentive medication- nifedipine. A patient with multiple dental care needs with GO, complicated by systemic risk factors would invariably benefit from multidisciplinary approach for care. A 57-year-old female was diagnosed with chronic periodontitis, nifedipine-induced GO and metabolic syndrome. Management encompassed initial nonsurgical periodontal therapy, where the patient was educated and guided towards better plaque control, following which, scaling, root debridement, and surgical therapy (gingivectomy and excisional new attachment procedure) were carried out. Along with periodontal therapy, she was also managed through restorative phase where a successful outcome was achieved. She was then followed-up with maintenance care, and nifedipine was substituted with captopril by the Physician to facilitate maintenance.

Keywords: Metabolic syndrome, Gingivectomy, Drug-induced gingival overgrowth, Periodontitis, Excisional new attachment procedure


  1. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Carranza’s Clinical Periodontology for south asia.11 th edition; saunders. St. Louis, Missouri. 2012.
  2. Beaumont J, Chesterman J, Kellett M, Durey K. Gingival overgrowth. Part 1: Aetiology and clinical diagnosis. Bri Dent Jour. 2017;222:85–91.
  3. Nibali L, Takarakis N, Needleman I, Tu YK, Aiuto D, Rizzo F, et al. Association between metabolic syndrome and periodontitis; A systematic review and meta analysis. The J of CliniEndoc and Meta. 2013;98:913–920. Available from: https://doi.org/10.1210/jc.2012-3552
  4. Andriankaja OM, Sreenivasa S, Dunford D, Denardin E. Association between metabolic syndrome and periodontal disease. Austr Dent Jour. 2010;55:252–259.
  5. Cohen ES. Atlas of Periodontal Surgery. (p. 10) 1988.
  6. Lucija B, Anna M, Iran A. Drug induced gingival overgrowth in cardiovascular patients. World J Cardiol. 2021;13(4):68–75.
  7. Gariuc A, Foia LG, Minea B, Luchian AI, Surdu AE, Toma V, et al. Drug induced gingival hyperplasia- experimental model. Rom J morphol Embryol. 2017;58:1371–1376.
  8. Grundy SM. A constellation of complications. The metabolic syndrome. Clinical cornerstone. Elsevier. 2005;7:35–36.
  9. Nibali L, Takarakis N, Needleman I, Tu YK, Aiuto D, Rizzo F, et al. Association between metabolic syndrome and periodontitis; A systematic review and meta analysis. The J of Clini Endoc and Meta. 2013;98:913–920.
  10. Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylar R. Periodontitis and diabetes - a two way relationship. Diabetology. 2012;55:21–31.
  11. Livada R, Shiloah J. Calcium channel blocker- induced gingival enlargement. J Hum Hypertens. 2014;28:10–14.
  12. Koirala PK, Pradhan S, Gorkhali RS. Gingival enlargement Management in Bir Hospital. A case series. J Nepal Soc Perio Oral Implant. 2017;1(2):84–90.


© 2021 Published by International Dental Educationists’ Association (IDEA). This is an open-access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/)


Subscribe now for latest articles, news.